Biogen Reports $2.53 Billion Revenue in Q3 2025, Driven by VUMERITY and SKYCLARYS Sales

Biogen Inc. reported a total revenue of $2.53 billion for the third quarter of 2025, marking a 2.8% increase from $2.47 billion in the same period last year. The company's product revenue rose by 4.4% to $1.85 billion, driven by a 15% increase in U.S. sales of VUMERITY, which reached $214.6 million, and a notable contribution from the newly launched SKYCLARYS, generating $132.9 million. However, the overall revenue growth was tempered by a decline in global TECFIDERA sales, which fell by 27.7% due to increased competition from generics. Net income attributable to Biogen for the quarter was $466.5 million, or $3.17 per diluted share, compared to $388.5 million, or $2.66 per diluted share, in the prior year, reflecting a 19.2% increase in earnings per share.

In terms of operational changes, Biogen has been actively pursuing strategic acquisitions and collaborations. The company announced its intention to acquire Alcyone Therapeutics for $85 million, focusing on pediatric care through innovative drug delivery systems. Additionally, Biogen has entered into a funding agreement with Royalty Pharma to co-fund development costs for the litifilimab program, which is expected to enhance its pipeline in neurology and rare diseases. The company also reported a significant milestone payment of $150 million related to its acquisition of HI-Bio, reflecting ongoing investments in its therapeutic pipeline.

Biogen's research and development expenses decreased by 15.5% to $436.1 million for the quarter, attributed to cost-saving measures under its "Fit for Growth" program, which aims to streamline operations and reduce expenses. The company anticipates achieving approximately $1 billion in gross operating expense savings by the end of 2025. The reduction in R&D spending was partially offset by increased clinical trial costs for key programs, including litifilimab and felzartamab. Selling, general, and administrative expenses saw a slight increase of 1.1% to $594.8 million, driven by operational spending related to product launches.

Biogen's balance sheet showed a significant improvement, with cash, cash equivalents, and marketable securities totaling approximately $4 billion as of September 30, 2025, up from $2.4 billion at the end of 2024. This increase was primarily due to strong cash flows from operations, despite higher tax payments and milestone obligations. The company’s total liabilities decreased significantly, primarily due to the redemption of its 4.050% Senior Notes, which contributed to a current liabilities reduction of 40.5%. Looking ahead, Biogen expects continued revenue growth from its rare disease portfolio and ongoing product launches, although it remains cautious about the impact of increasing competition and pricing pressures in the biopharmaceutical market.